Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and Cellcept
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CNI Side Effects
Conditions
CNI Side Effects
Trial Timeline
Oct 1, 2006 → Apr 3, 2014
NCT ID
NCT01062555About Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and Cellcept
Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and Cellcept is a phase 1/2 stage product being developed by Roche for CNI Side Effects. The current trial status is completed. This product is registered under clinical trial identifier NCT01062555. Target conditions include CNI Side Effects.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01062555 | Phase 1/2 | Completed |
Competing Products
6 competing products in CNI Side Effects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo | AstraZeneca | Phase 1 | 33 |
| Epanova® (omega-3 carboxylic acids) + corn oil control | AstraZeneca | Phase 3 | 77 |
| deferasirox | Novartis | Pre-clinical | 23 |
| deferasirox: | Novartis | Approved | 85 |
| Moxifloxacin 400 mg | Bayer | Approved | 82 |
| Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine | Rigel Pharmaceuticals | Phase 1/2 | 33 |